Supernus sues Par for Trokendi XR patents infringement

19 January 2015

US drugmaker Supernus Pharmaceuticals (Nasdaq: SUPN) says it has sued privately-held generics firm Par Pharmaceutical for infringement of four patents covering its antiepileptic drug Trokendi XR (topiramate). Supernus shares closed up 4.15% at $9.04 on Friday, after the announcement.

Supernus says its US Patents Nos 8,298,576, 8,298,580, 8,663,683 and 8,877,248 cover once-a-day topiramate formulations and methods of treating seizures using those formulations. Patent protection for Trokendi XR expires no earlier than 2027, according to the company, which last month received a Paragraph IV Notice Letter from Par advising of the filing by Par of an Abbreviated New Drug Application seeking approval for topiramate extended-release capsules, a potential generic version Trokendi XR (The Pharma Letter December 9, 2014).

Filing automatically prevents FDA from approving Par's ANDA for 30 months.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK